Allogeneic hematopoietic stem cell transplantation for advanced extranodal natural killer/T-cell lymphoma, nasal type

Daisuke Ennishi, Yoshinobu Maeda, Nobuharu Fujii, Eisei Kondo, Katsuji Shinagawa, Kazuma Ikeda, Koichi Ichimura, Tadashi Yoshino, Mitsune Tanimoto

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The prognosis for patients with advanced or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type (ENKL) is extremely poor. Thus, allogeneic stem cell transplantation (allo-HSCT) should be considered for this disease. However, reports of allo-HSCT for ENKL are limited because of the rarity of the disease. Here, we describe the clinical course of 12 cases of advanced and refractory ENKL treated with allo-HSCT, including five cases with cord blood transplant. With a median follow-up of 13 months (range, 1-168 months), seven patients are alive in remission, five have died, and one treatment-related death occurred. All patients with disease progression at transplant died of disease progression, whereas seven of eight patients with a complete or partial response are long-term survivors. Allo-HSCT is a feasible and promising consolidation therapy for advanced and relapsed ENKL. The disease status before allo-HSCT is well associated with general outcome, and thus induction treatment is very important for this disease.

Original languageEnglish
Pages (from-to)1255-1261
Number of pages7
JournalLeukemia and Lymphoma
Volume52
Issue number7
DOIs
Publication statusPublished - Jul 2011

Keywords

  • Extranodal NK/T-cell lymphoma
  • allogeneic stem cell transplantation
  • cord blood transplant
  • nasal type

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Allogeneic hematopoietic stem cell transplantation for advanced extranodal natural killer/T-cell lymphoma, nasal type'. Together they form a unique fingerprint.

  • Cite this